Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Network Oncology Registry
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Network Oncology was a biopharmaceutical company focused on the development and commercialization of oncology therapeutics, specifically targeting multi-drug resistant cancers. The company's lead candidate, BOS-948 (formerly known as NO-101), was a novel tubulin inhibitor designed to overcome common resistance mechanisms in solid tumors such as ovarian and lung cancer. Network Oncology was eventually acquired by Bionomics, which integrated the oncology assets into its own pipeline to leverage the potential of the tubulin-binding agent technology.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Network Oncology Registry.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Network Oncology Registry.